EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity.

Kellie Lucken Laura O'Regan Jene ChoiJosephina SampsonSarah L Pashley Richard Bayliss Sam Khan Andrew M Fry

Published in: Molecular cancer research : MCR (2022)

This study suggests that combining the microtubule poison, paclitaxel, with targeted ALK inhibitors may provide an effective new treatment option for patients with NSCLC with tumors that express the EML4-ALK V3 oncogenic fusion.

Keyphrases

advanced non small cell lung cancer
cell cycle
small cell lung cancer
epidermal growth factor receptor
dna damage
cancer therapy
emergency department
combination therapy
adverse drug
drug induced